Compound class:
Synthetic organic
Comment: YCT529 is an oral retinoic acid receptor alpha (RAR-α) antagonist, that is being investigated as a non-hormonal male contraceptive. Its development and function were presented at the spring meeting of the American Chemical Society (ACS) in March 2022. Antagonising RAR-α disrupts spermatogenesis. YCT529 is formulated as a sodium salt. The RAR-α-selective antagonists BMS-189532 and BMS-189614 have been reported previously [1-2].
|
|
Bioactivity Comments |
We have been unable to find publicly available, quantitative biological data for the interaction of this ligand with its protein target. |